Molina: Navigating in Healthcare

07/15/2014 8:00 am EST

Focus: STOCKS

Michael Cintolo

Vice President of Investments and Chief Analyst, Cabot Heritage Corporation

This new recommendation is a company that has been helping customers navigate the maze of government healthcare rules and regulations since 1980, explains Mike Cintolo, editor of Cabot Top Ten Trader.

Specializing in the low-income market, Molina Healthcare (MOH) got its start with such government programs as SCHIP (State Children’s Health Insurance Program) and Medicaid before expanding into Medicare in 2006.

Currently, Molina services more than 2.1 million members, offering Medicaid programs in 15 states and Medicare options in another eight. The stock’s recent strength has come as a result of speculation about Molina’s second-quarter earnings report, slated for release on July 30.

Specifically, analyst estimates are rising, heading into the report, with Molina most recently attracting a buy rating from analysts at Sterne Agee.

Overall, the company has a history of strong revenue growth, with sales growing at double-digit rates in each year of the past decade. Furthermore, projections are pointing toward a rise of 48% this year, followed by 40% growth in 2015.

The continued expansion of government influence in the healthcare market is a primary driver for Molina’s revenue. While such rapid expansion sometimes causes glitches in the system, we really like Molina’s potential for growth.

After consolidating for roughly the first four months of 2014, MOH has taken off. The stock bottomed near $33 in mid-April before rebounding sharply over the next month, ultimately pulling its 10-day and 50-day moving averages into a bullish cross.

Following a rapid rise in early May, MOH has settled into a more gradual rally. In June, MOH met with resistance in the $45 region, which led to a successful test of support near the 25-day trendline.

In fact, MOH bounced sharply from this trendline, on strong volume, and is now perched at an all-time high just north of $46. With earnings on the horizon, you can buy on pullbacks too, if you are game.

Subscribe to Cabot Top Ten Trader here…

More from MoneyShow.com:

Pfizer: Top Pick in Pharma

"Valeant" Effort for Contrarians

Magellan Health: Psychiatric Profits

Related Articles on STOCKS